WALTHAM, Mass. and MADRID, Jan. 19 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. and LABEC Pharma, S.L. announced today that LABEC Pharma has met European regulatory guidelines to sell Interleukin Genetics’ Heart Health genetic test. The test, which helps to identify individuals at elevated risk for early heart attack, will be marketed to physicians in Spain and Portugal by LABEC Pharma under the product name Cardio Health(TM). Samples will be processed at Interleukin Genetics’ CLIA-certified laboratory in Waltham, MA and the Company will receive royalties and processing fees for each test sold.
“We are pleased to begin our partnership with LABEC Pharma on distribution of our Cardio Health(TM) genetic test to the physician community in two European Countries,” said Lewis H. Bender, CEO, Interleukin Genetics, Inc. “Physicians will now have the opportunity to identify patients at elevated risk for heart attack due to chronic underlying inflammation and recommend the appropriate action to improve health outcomes.”
About Interleukin Genetics
About LABEC Pharma
LABEC Pharma, S.L. is a leading distributor of advanced diagnostic tests, with presence in Europe and Latin America. Focused on identifying state-of-the-art diagnostics, LABEC Pharma has partnership agreements with the leading hospitals and reference labs in the countries in which it operates, to make available those tests to physicians and patients. Amongst its products, LABEC Pharma distributes HPV OncoTect, a high predictive value early diagnostic test for cervical cancer. LABEC Pharma is headquartered in Madrid, Spain. For more information about LABEC Pharma, its products and ongoing programs, please visit: http://www.labec.net.
CONTACT: Media: Erin Walsh of Interleukin Genetics, +1-781-419-4707,
ewalsh@ilgenetics.com; or Cristina Guillen of LABEC Pharma,
+34-91-515-91-71, cguillen@labec.net
Web site: http://www.ilgenetics.com/
